journal
MENU ▼
Read by QxMD icon Read
search

Drugs

journal
https://www.readbyqxmd.com/read/29785563/authors-reply-to-pires-et-al-switching-reference-medicines-to-biosimilars-a-systematic-literature-review-of-clinical-outcomes
#1
LETTER
Hillel P Cohen, Andrew Blauvelt, Robert M Rifkin, Silvio Danese, Sameer B Gokhale, Gillian Woollett
No abstract text is available yet for this article.
May 21, 2018: Drugs
https://www.readbyqxmd.com/read/29785562/comment-on-switching-reference-medicines-to-biosimilars-a-systematic-literature-review-of-clinical-outcomes
#2
LETTER
Antonio Pires, Kavitha Goyal, Andrew Greenspan
No abstract text is available yet for this article.
May 21, 2018: Drugs
https://www.readbyqxmd.com/read/29766394/treatment-of-eosinophilic-granulomatosis-with-polyangiitis-a-review
#3
Loïc Raffray, Loïc Guillevin
Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) is a rare type of anti-neutrophil cytoplasm antibody-associated vasculitis. Nevertheless, eosinophilic granulomatosis with polyangiitis stands apart because it has features of vasculitis and eosinophilic disorders that require targeted therapies somewhat different from those used for other anti-neutrophil cytoplasm antibody-associated vasculitides. Considerable advances have been made in understanding the underlying pathophysiology of eosinophilic granulomatosis with polyangiitis that have highlighted the key role of eosinophils and opened new therapeutic opportunities...
May 15, 2018: Drugs
https://www.readbyqxmd.com/read/29761382/latanoprostene-bunod-ophthalmic-solution-0-024-a-review-in-open-angle-glaucoma-and-ocular-hypertension
#4
Sheridan M Hoy
Latanoprostene bunod ophthalmic solution 0.024% (hereafter referred to as latanoprostene bunod 0.024%) [Vyzulta™] is a nitric oxide (NO)-donating prostaglandin F2α analogue approved in the USA for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. It is thought to lower IOP by increasing aqueous humour outflow through the uveoscleral pathway (mediated by latanoprost acid) and increasing the facility of aqueous humour outflow through the trabecular meshwork pathway (mediated by NO)...
May 14, 2018: Drugs
https://www.readbyqxmd.com/read/29754293/chemotherapy-induced-neutropenia-as-a-prognostic-and-predictive-marker-of-outcomes-in-solid-tumor-patients
#5
REVIEW
Pashtoon Murtaza Kasi, Axel Grothey
Chemotherapy-induced neutropenia (CIN) is one of the most common side effects seen in cancer patients. As an adverse event, it is deemed undesirable since it often constitutes a dose-limiting toxicity for cytotoxic agents leading to treatment delays and/or dose reductions. It is also associated with a financial cost component from diagnostic work-up and treatment of patients with chemotherapy-induced febrile neutropenia (CIFN). Neutropenia is commonly accompanied by a decrease in other hematopoietic lineages (anemia and/or thrombocytopenia)...
May 12, 2018: Drugs
https://www.readbyqxmd.com/read/29752706/tildrakizumab-first-global-approval
#6
Anthony Markham
Merck & Company Inc. have developed tildrakizumab (tildrakizumab-asmn; Ilumya™), a high-affinity, humanised IgG1 κ monoclonal antibody that specifically targets interleukin-23 p19, as a treatment for chronic plaque psoriasis. The drug was recently approved for marketing by the US FDA based on positive results from the phase III reSURFACE clinical trial programme in patients with chronic plaque psoriasis. This article summarizes the milestones in the development of tildrakizumab leading to this first approval for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy...
May 11, 2018: Drugs
https://www.readbyqxmd.com/read/29748749/correction-to-imipenem-relebactam-and-meropenem-vaborbactam-two-novel-carbapenem-%C3%AE-lactamase-inhibitor-combinations
#7
George G Zhanel, Courtney K Lawrence, Heather Adam, Frank Schweizer, Sheryl Zelenitsky, Michael Zhanel, Philippe R S Lagacé-Wiens, Andrew Walkty, Andrew Denisuik, Alyssa Golden, Alfred S Gin, Daryl J Hoban, Joseph P Lynch, James A Karlowsky
Section heading 5.2, which currently reads 5.2 Meropenem-Relebactam.
May 10, 2018: Drugs
https://www.readbyqxmd.com/read/29737499/vaccines-targeting-pcsk9-a-promising-alternative-to-passive-immunization-with-monoclonal-antibodies-in-the-management-of-hyperlipidaemia
#8
Stefan Weisshaar, Markus Zeitlinger
Hypercholesterolaemia is frequently observed in patients with cardiovascular diseases (CVD) and is associated with increased mortality. Statin treatment has been the standard of care for reducing low-density lipoprotein cholesterol (LDL-C) to improve cardiovascular outcomes. However, statins have limited effects in some patients and may be discontinued due to adverse effects resulting in LDL-C above target levels. The proprotein convertase subtilisin kexin type 9 (PCSK9) is a pivotal regulator in the LDL-C metabolism by degrading the LDL-C receptor on hepatocytes...
May 8, 2018: Drugs
https://www.readbyqxmd.com/read/29737498/management-of-embolic-stroke-of-undetermined-source-esus
#9
REVIEW
Tobias Geisler, Annerose Mengel, Ulf Ziemann, Sven Poli
According to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification, embolic stroke of undetermined source (ESUS) has refined the old definition of cryptogenic stroke. More sophisticated criteria and a well-defined diagnostic workup point out the embolic nature of this disease. Because ESUS is associated with a high stroke recurrence, a clear risk prediction and management is of utmost importance to improve prognosis. To date, standard pharmacotherapy consists of antiplatelet drugs and statins...
May 8, 2018: Drugs
https://www.readbyqxmd.com/read/29728984/correction-to-apatinib-a-review-in-advanced-gastric-cancer-and-other-advanced-cancers
#10
Lesley J Scott
An Online First version of this article was made available online at http://link.springer.com/journal/40265/onlineFirst/page/1 on 16 April 2018. Errors were subsequently identified in the article, and the following corrections should be noted.
May 4, 2018: Drugs
https://www.readbyqxmd.com/read/29687421/baricitinib-a-review-in-rheumatoid-arthritis
#11
Zaina T Al-Salama, Lesley J Scott
Baricitinib (Olumiant® ) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). This novel, small molecule is approved for use as monotherapy, or in combination with methotrexate, for the treatment of adults with moderate to severe active RA who responded inadequately to or were intolerant of ≥ 1 DMARD. In pivotal multinational trials, once-daily baricitinib 4 mg, with/without methotrexate (± another csDMARD), improved the signs and symptoms of RA, disease activity and physical function in DMARD-naive patients and in patients with an inadequate response to methotrexate, csDMARDs or TNF inhibitors; baricitinib treatment also slowed structural joint damage in DMARD-naive patients and in those with an inadequate response to methotrexate and csDMARDs...
April 23, 2018: Drugs
https://www.readbyqxmd.com/read/29679282/burosumab-first-global-approval
#12
Yvette N Lamb
Burosumab (Crysvita® ; Kyowa Hakko Kirin Co., Ltd. and Ultragenyx Pharmaceutical Inc.) is a fully human monoclonal antibody directed at fibroblast growth factor 23 (FGF23). Excessive FGF23 production has been implicated in various hypophosphataemic diseases. Inhibition of FGF23 by burosumab results in increased renal phosphate reabsorption and increased serum levels of phosphorus and active vitamin D. In February 2018, the EMA granted subcutaneous burosumab conditional marketing authorization for the treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons...
April 20, 2018: Drugs
https://www.readbyqxmd.com/read/29679281/correction-to-onabotulinumtoxina-a-review-in-the-prevention-of-chronic-migraine
#13
James E Frampton, Stephen Silberstein
The article OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine, written by James E. Frampton and Stephen Silberstein, was originally published Online First without open access. After publication in volume 78, issue 5, pages 589-600 [funder] requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by [funder]. Further details may be found at [MedEngine webpage link].
April 20, 2018: Drugs
https://www.readbyqxmd.com/read/29675744/ibalizumab-first-global-approval
#14
Anthony Markham
TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)-a humanised IgG4 monoclonal antibody-as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS. This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment.
April 19, 2018: Drugs
https://www.readbyqxmd.com/read/29671219/ceftazidime-avibactam-a-review-in-the-treatment-of-serious-gram-negative-bacterial-infections
#15
Matt Shirley
Ceftazidime-avibactam (Zavicefta® ) is an intravenously administered combination of the third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase inhibitor avibactam. In the EU, ceftazidime-avibactam is approved for the treatment of adults with complicated urinary tract infections (cUTIs) [including pyelonephritis], complicated intra-abdominal infections (cIAIs), hospital-acquired pneumonia (HAP) [including ventilator-associated pneumonia (VAP)], and other infections caused by aerobic Gram-negative organisms in patients with limited treatment options...
April 18, 2018: Drugs
https://www.readbyqxmd.com/read/29663292/the-potential-role-of-sglt2-inhibitors-in-the-treatment-of-type-1-diabetes-mellitus
#16
Hadi Fattah, Volker Vallon
Type 1 diabetes mellitus is a difficult disease to treat due to the relative paucity of therapeutic options other than injectable insulin. The latter, however, can induce hypoglycemia, which has been linked to enhanced cardiovascular risk. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral anti-hyperglycemic medications that do not increase the hypoglycemia risk and are US Food and Drug Administration (FDA) approved in type 2 diabetes mellitus. SGLT2 inhibitors may also be of benefit in type 1 diabetic patients, in addition to insulin, although they have not yet been approved for this indication...
April 16, 2018: Drugs
https://www.readbyqxmd.com/read/29663291/apatinib-a-review-in-advanced-gastric-cancer-and-other-advanced-cancers
#17
Lesley J Scott
Apatinib [AiTan™ (China); Rivoceranib® (global)] is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas...
April 16, 2018: Drugs
https://www.readbyqxmd.com/read/29651740/the-expanding-role-of-ketamine-in-the-emergency-department
#18
Sophia Sheikh, Phyllis Hendry
Patients frequently come to the emergency department for pain. For decades, ketamine has been used in the emergency department for procedural sedation but is now receiving attention as a potential alternative to opioids because of its unique analgesic effects. Additionally, ketamine's dissociative properties have made it a popular choice for sedating profoundly agitated patients. In this narrative review, these new roles for ketamine in the emergency department are discussed.
April 12, 2018: Drugs
https://www.readbyqxmd.com/read/29626324/apalutamide-first-global-approval
#19
Zaina T Al-Salama
Apalutamide (ErleadaTM ) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC). It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens. In February 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC). Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochemically-relapsed PC...
April 6, 2018: Drugs
https://www.readbyqxmd.com/read/29623652/baloxavir-first-global-approval
#20
Young-A Heo
Baloxavir marboxil (Xofluza™; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections...
April 5, 2018: Drugs
journal
journal
26573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"